Summary
The main goal of the STARDUST project is to realize a novel wireless implantable and independent micro-scale device (200x200x200 µm3) enabling in-vivo electrophysiology, optogenetics and ultra-localized drug delivery in freely moving animals. The device will be used to target specific neural circuits of the brain and test a new therapeutic approach for Parkinson’s Disease (PD).
The methods used in this project are based on cutting-edge miniaturized technology combining integrated chips, microelectromechanical systems (MEMS), local drug delivery, integrated electrodes and micro-scale light emitting diodes (µLEDs). STARDUST will benefit from these advances and for the first time provide an implantable ultrasonically-powered miniaturized device for in-vivo optogenetics, local drug delivery and electrophysiological monitoring – all in one single device. The proposed device is expected to provide an output power of 1-20 mW/mm2 for optogenetics with two different wavelengths, one for neuron activation and one for triggering drug-delivery; STARDUST will provide proof of concept.
The main novelty of the STARDUST project is the convergence of multiple, interdisciplinary fields including optogenetics, triggered drug-delivery, miniaturized ultrasonic energy harvesting, material science and nanoelectronics. The main ambition of the project is to develop a new technology platform to be used for future implantable in-vivo optogenetic devices for monitoring and treating diseases, with an optional local drug delivery add-on beyond 2025. Establishing proof of concept of the STARDUST platform will be the foundation for other applications within photodynamic therapy such as cancer treatment and other neurological and non-neurological disorders.
The methods used in this project are based on cutting-edge miniaturized technology combining integrated chips, microelectromechanical systems (MEMS), local drug delivery, integrated electrodes and micro-scale light emitting diodes (µLEDs). STARDUST will benefit from these advances and for the first time provide an implantable ultrasonically-powered miniaturized device for in-vivo optogenetics, local drug delivery and electrophysiological monitoring – all in one single device. The proposed device is expected to provide an output power of 1-20 mW/mm2 for optogenetics with two different wavelengths, one for neuron activation and one for triggering drug-delivery; STARDUST will provide proof of concept.
The main novelty of the STARDUST project is the convergence of multiple, interdisciplinary fields including optogenetics, triggered drug-delivery, miniaturized ultrasonic energy harvesting, material science and nanoelectronics. The main ambition of the project is to develop a new technology platform to be used for future implantable in-vivo optogenetic devices for monitoring and treating diseases, with an optional local drug delivery add-on beyond 2025. Establishing proof of concept of the STARDUST platform will be the foundation for other applications within photodynamic therapy such as cancer treatment and other neurological and non-neurological disorders.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/767092 |
| Start date: | 01-10-2017 |
| End date: | 30-09-2022 |
| Total budget - Public funding: | 3 803 057,50 Euro - 3 787 932,00 Euro |
Cordis data
Original description
The main goal of the STARDUST project is to realize a novel wireless implantable and independent micro-scale device (200x200x200 µm3) enabling in-vivo electrophysiology, optogenetics and ultra-localized drug delivery in freely moving animals. The device will be used to target specific neural circuits of the brain and test a new therapeutic approach for Parkinson’s Disease (PD).The methods used in this project are based on cutting-edge miniaturized technology combining integrated chips, microelectromechanical systems (MEMS), local drug delivery, integrated electrodes and micro-scale light emitting diodes (µLEDs). STARDUST will benefit from these advances and for the first time provide an implantable ultrasonically-powered miniaturized device for in-vivo optogenetics, local drug delivery and electrophysiological monitoring – all in one single device. The proposed device is expected to provide an output power of 1-20 mW/mm2 for optogenetics with two different wavelengths, one for neuron activation and one for triggering drug-delivery; STARDUST will provide proof of concept.
The main novelty of the STARDUST project is the convergence of multiple, interdisciplinary fields including optogenetics, triggered drug-delivery, miniaturized ultrasonic energy harvesting, material science and nanoelectronics. The main ambition of the project is to develop a new technology platform to be used for future implantable in-vivo optogenetic devices for monitoring and treating diseases, with an optional local drug delivery add-on beyond 2025. Establishing proof of concept of the STARDUST platform will be the foundation for other applications within photodynamic therapy such as cancer treatment and other neurological and non-neurological disorders.
Status
CLOSEDCall topic
FETOPEN-01-2016-2017Update Date
27-04-2024
Images
No images available.
Geographical location(s)
Search
Organisations
-
| AARHUS UNIVERSITET (AU) (Coördinator)
-
| BIOMODICS APS
-
| CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
-
| FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
-
| HUMBOLDT-UNIVERSITAT ZU BERLIN
-
| SPINVERSE OY (SPINVERSE)
-
| SPINVERSE AB
-
| UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK
-
| Universidade Federal do Pará
-
| VIB VZW